Invention Grant
- Patent Title: Use of the CD2 signaling domain in second-generation chimeric antigen receptors
-
Application No.: US14375999Application Date: 2013-02-22
-
Publication No.: US09783591B2Publication Date: 2017-10-10
- Inventor: Carl H. June , John Scholler , Avery D. Posey, Jr.
- Applicant: The Trustees of the University of Pennsylvania
- Applicant Address: US PA Philadelphia
- Assignee: The Trustees of the University of Pennsylvania
- Current Assignee: The Trustees of the University of Pennsylvania
- Current Assignee Address: US PA Philadelphia
- Agency: Saul Ewing LLP
- Agent Kathryn Doyle
- International Application: PCT/US2013/027361 WO 20130222
- International Announcement: WO2013/126729 WO 20130829
- Main IPC: C07K14/705
- IPC: C07K14/705 ; C07K14/725 ; C12N15/85 ; C07K16/28 ; C07K16/30
Abstract:
The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.
Public/Granted literature
- US20140370045A1 USE OF THE CD2 SIGNALING DOMAIN IN SECOND-GENERATION CHIMERIC ANTIGEN RECEPTORS Public/Granted day:2014-12-18
Information query
